Colangite esclerosante primária
Palavras-chave:
colangite esclerosante, colestase, transplante hepáticoResumo
Os autores apresentam uma revisão ampla com os novos conhecimentos sobre a colangite esclerosante primária (CEP), doença colestática crônica de origem autoimune. Embora não se trate de uma doença muito prevalente na prática clínica, é de extrema importância que o clínico geral conheça os principais sintomas e sinais da CEP, as doenças associadas, os métodos diagnósticos e o momento exato de encaminhar o paciente para um centro especializado. Enfocam a dificuldade do tratamento clínico e a tendência evolutiva da doença para a cirrose biliar e para a necessidade do transplante hepático.
Referências
Saffioti F, Mavroeidis V. Review of incidence and outcomes of treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis. World J Gastroenterology 2021 oct 15; 13(10): 1336-1366.
Bambha K, Kim WR, Talwalkar J, et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003;125:1364-9.
Lindkvist B, Benito de Valle M, Gullberg B, et al. Incidence and prevalence of primary scler osing cholangitis in a defined adult population in Sweden. Hepatology 2010;52:571-7.
Milkiewicz M, Klak M, Kempinska-Podhorodecka A, et al. Impaired hepatic adaptation to chronic cholestasis induced by primary sclerosing cholangitis. Sci Rep 2016;6:39573.
Hohenester S, Wenniger LM, Paulusma CC, et al. A biliary HCO3- umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes. Hepatology 2012;55:173-83.
Lunder AK, Hov JR, Borthne A, et al. Prevalence of sclerosing cholangitis detected by magnetic resonance cholangiography in patients with long-term inflammatory bowel disease. Gastroenterology 2016;151:660-9.e4.
Weismüller TJ, Trivedi PJ, Bergquist A, et al. International PSC Study Group. Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. Gastroenterology 2017; 152: 1975-1984.e8 [PMID: 28274849 doi: 10.1053/j.gastro.2017.02.038]
Broomé U, Bergquist A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin Liver Dis 2006;26:31-41.
Bambha K, Kim WR, Talwalkar J, et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003;125:13.
Abdalian R, Heathcote EJ. Sclerosing cholangitis: a focus on secondary causes. Hepatology 2006;44:1063-74.
Corpechot C, Gaouar F, El Naggar A, et al. Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis. Gastroenterology. 2014; 146:970–9795. Rabiee R, Silveira MG. Primary sclerosing cholangitis. Transl Gastroenterol Hepatol 2021; 6:29.
Ludwig J, Barham SS, LaRusso NF, Elveback LR, Wiesner RH, McCall JT. Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology, 1 (1981), pp. 632-640.
Björnsson E, Olsson R, Bergquist A, et al. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology 2008;134:975-80.
Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med. 1997 Mar 6;336(10):691-5.
Fickert P, Hirschfield GM, Denk G, et al. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. J Hepatol 2017;67:549-58.
Kowdley KV, Vuppalanchi R, Levy C, et al. A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis. J Hepatol 2020;73:94-101.
Mansour JC, Aloia TA, Crane CH, Heimbach JK, Nagino M, Vauthey JN. Hilar cholangiocarcinoma: expert consensus statement. HPB (Oxford) 2015; Aug;17(8):691-9.
Mazzaferro V, Gorgen A, Roayaie S, Droz Dit Busset M, Sapisochin G. Liver resection and transplantation for intrahepatic cholangiocarcinoma. J Hepatol 2020; 72: 364-377.
Azad AI, Rosen CB, Taner T, Heimbach JK, Gores GJ. Selected Patients with Unresectable Perihilar Cholangiocarcinoma (pCCA) Derive Long-Term Benefit from Liver Transplantation. Cancers (Basel) 2020; 12 [PMID: 33121179 doi: 10.3390/cancers12113157] 117.
